Current Headlines

  1. Berkeley Lights Launches Plasma B Cell Antibody Discovery Workflow On The Beacon® Optofluidic Platform

    Berkeley Lights, Inc. (BLI), a leader in digital cell biology, announced today the release of a plasma B cell antibody discovery workflow for use on the Beacon Optofluidic Platform

  2. Horizon Pharma plc And HemoShear Therapeutics Enter Into Exclusive Drug Discovery Collaboration In Gout

    Horizon Pharma plc and HemoShear Therapeutics, LLC, a privately held biotechnology company, recently announced a collaboration to discover and develop novel therapeutics for gout

  3. Ablexis Announces Licensing Agreement With Corvidia Therapeutics

    Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, recently announced a license agreement with Corvidia Therapeutics Inc

  4. A New 'Atlas' Of Genetic Influences On Osteoporosis

    A ground-breaking new study led by researchers from the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) has succeeded in compiling an atlas of genetic factors associated with estimated bone mineral density (BMD), one of the most clinically relevant factors in diagnosing osteoporosis

  5. Novartis Provides Data To SPARK, Pew's Platform For Antibiotic Discovery Research

    The Pew Charitable Trusts announced today that Novartis has shared data from its antibiotic research programs on Pew's open-access Shared Platform for Antibiotic Research and Knowledge (SPARK)

  6. Clarivate Analytics Launches Advanced Predictive Analytics Solution To Help Accelerate Drug Development

    Clarivate Analytics has launched an advanced predictive analytics tool, Cortellis Analytics – Drug Timeline and Success Rates (DTSR), part of the Cortellis suite of intelligence solutions for drug development and commercialization

  7. Kiniksa Announces Active U.S. Investigational New Drug Application For Mavrilimumab

    Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a clinical study of mavrilimumab in subjects with giant cell arteritis (GCA). U.S. subjects will be included in the ongoing, global Phase 2 clinical trial, in which dosing has already commenced in multiple countries

  8. ProQR Receives Fast Track Designation From FDA For QR-421a For Usher Syndrome Type 2

    (GLOBE NEWSWIRE) - ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene

  9. Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining Its Alphalex™ Technology With An Approved PARP Inhibitor To Treat Various Solid Tumors In Combination With Chemotherapy

    Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor-targeting platform, today announced that it has selected CBX-11 as its lead clinical development candidate for the treatment of patients with various solid tumors

  10. Ascletis' IND Filing For Its Third HCV Drug ASC21 Accepted By NMPA

    Ascletis Pharma Inc. (1672.HK), a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that the investigational new drug application (IND) for its third HCV drug ASC21 was accepted by the National Medical Products Administration (NMPA)